HLS and Harlan Laboratories to Operate Under New Brand and Name
News Feb 25, 2015
Two core business units of Research Model and Services (RMS) and Contract Research Services (CRS) have been established from existing capabilities across Harlan and HLS, as well as subsidiaries of both companies. The RMS business unit provides high-quality research models, lab animal diets and bedding, and support services from 30 sites worldwide.
The CRS business unit offers a comprehensive range of drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC, and regulatory consultancy from nine contract research facilities within Europe, the US and the Middle East.
Throughout this process, both companies have kept customer relationships as the central consideration, and the new company will be able to deliver a far broader range of products and services to their customers from more global locations.
Brian Cass, CEO, commented: “The decision to rebrand the two companies as one entity is the natural progression of a sustained integration process that was put in place last year. It is a symbol of the fact that as one integrated company we are now able to further diversify the range of products and services we can provide to the market, further supporting existing relationships whilst growing our business globally with new customers. It’s a hugely exciting time for our company, with our customer-led focus and flexibility in approach, our goal is to establish our new company as the number one development partner for customer service and scientific expertise.”
The combined company has 3,500 staff and sales approaching $500 million. As a result of the integration, the company is already the largest provider of research services to the crop protection and chemical industries, the second largest supplier of research models and services, and the third largest in the preclinical pharmaceutical development arena.
The formal rebrand completion date is yet to be finalized, with full execution and implementation later this year.
Postpartum hemorrhaging is the world's leading cause of death for women during and after childbirth, and the third-leading cause in the United States alone. The drug 'misoprostol' although affordable, has dangerous side effects, including uterine cramping, heart attack, toxicity in the brain and spinal cord, fetal death and fetal heart abnormalities. Development of a safer drug may be on the horizon, based on new researchREAD MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019